08 March 2024
08 March 2024
Integrating Ambrx's ADC technology into J&J's portfolio will aid in advancing the development of targeted oncology therapies.
The approval is based on data from the Phase III CheckMate –901 clinical trial involving 608 patients.
Sionna could have four candidates in clinical trials in 2024 amid a cystic fibrosis landscape dominated by Vertex.
Ganaxolone offered a 30% reduction in 28-day seizure frequency versus 6.5% in the placebo arm of its trial.
AI remained one of the main talking points at CTS Europe, as the roadmap for generative AI was mapped out.
Taletrectinib is one of the first agents to provide segmented efficacy data on ROS1-positive NSCLC patients based on their line of therapy.
The space will function as a manufacturing base for the next-generation pneumococcal conjugate vaccine candidate GBP410.
Citius Pharmaceuticals’ CEO detailed plans to launch its lymphoma therapy Lymphir in Autumn 2024, as it awaits a PDUFA date.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
